Claudia Altobelli

Claudia Altobelli

Auto-generated profile, based on publicly available information

Claudia Altobelli

Department of Critical Area, Nephrology and Dialysis Unit Cotugno Hospital – AORN Ospedali dei Colli Naples Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
CAClaudia Altobelli
Claudia Altobelli
PAPietro Anastasio
Pietro Anastasio
ACAlessandro Cerrone
Alessandro Cerrone
ESElisabetta Signoriello
Elisabetta Signoriello
GLGiacomo Lus
Giacomo Lus
GCGiovanna Capolongo
Giovanna Capolongo
Background: Therapeutic plasmapheresis (TP) is an extracorporeal therapy that allows the removal of pathogens from plasma. The role of TP in immuno-mediated diseases and toxic conditions has been of interest for decades. Summary: We reviewed the recent literature on the application and the optimal choice of TP technique ranging from plasma exchange, double filtration plasmapheresis, rheopheresis, immunoadsorptions, plasma adsorption perfusion and lipidoapheresis. In addition, we report our experience in the application of TP for various diseases ranging in different medical specialties, following the American Society for Apheresis (ASFA) recommendations. Key Messages: Overall patients receiving TP showed an improvement in clinical and laboratory parameters. Our review and single-center experience suggest a benefit of the application of TP in multiple clinical disciplines.

23 March 2017 in Nephron
Verified
Journal Article
Closed access
PDF file
PAPietro Anastasio
Pietro Anastasio
DVDavide Viggiano
Davide Viggiano
MZmiriam zacchia
miriam zacchia
CAClaudia Altobelli
Claudia Altobelli
GCGiovambattista Capasso
Giovambattista Capasso
NSNatale Gaspare De Santo
Natale Gaspare De Santo
Background/Aims: Little information is available about the tubular functions and the renal adjustments that take place in obese subjects after a protein meal. How the excess fat may affect renal response to dietary proteins is currently only partially understood. This paper aims to address (i) whether severe obesity, in the absence of other comorbidities, is responsible of kidney dysfunction at either the glomerular or the tubular level and (ii) whether it compromises renal adaptations to a large protein meal. Methods: Twenty-eight obese subjects without albuminuria, along with 20 control subjects, age and gender matched, have been studied. The glomerular filtration rate (GFR; inulin clearance), renal plasma flow (p-aminohippurate clearance), the proximal tubular function (lithium clearance), the fractional excretion of sodium (FPRNa) have been measured at the basal level (steady state) and after a protein meal (perturbation). Results: Under steady state conditions, filtration fraction, proximal tubular sodium handling and the FPRNa were not significantly different in non proteinuric obese subjects compared with controls. However, a protein meal led to a delayed glomerular hyperfiltration in obese patients compared with controls. Conclusion: This study shows that obese patients, in the absence of significant comorbidities, have a normal proximal tubule Na+ absorption at basal; conversely, these subjects showed a different response to a protein meal compared with normal subjects in terms of changes of GFR. Overall, these results suggest that the modified hemodynamic response to a protein meal might be the earliest hallmark of future kidney dysfunction in obese subjects.

6 August 2024 in Journal of Clinical Apheresis
Verified
Journal Article
Open access
CAClaudia Altobelli
Claudia Altobelli
FFFilippo Carone Fabiani
Filippo Carone Fabiani
PAPietro Anastasio
Pietro Anastasio
CPCorrado Pluvio
Corrado Pluvio
EPEmanuela de Pascale
Emanuela de Pascale
GCGiovanna Capolongo
Giovanna Capolongo
Background: Peripheral artery disease (PAD) in hemodialysis (HD) patients has a significant social impact due to its prevalence, poor response to standard therapy and dismal prognosis. Rheopheresis is indicated by guidelines for PAD treatment.Materials and Methods: Twenty‐five HD patients affected by PAD stage IV Lerichè‐Fontaine and ischemic ulcer 1C or 2C according to the University of Texas Wound Classification System (UTWCS), without amelioration after traditional medical therapy and/or revascularization, were selected and underwent 12 Rheopheresis sessions in 10 weeks. Improvements in pain symptoms using Numerical Rating Scale (NRS), healing ulcers and laboratory hemorheological parameters have been evaluated.Results: A clinically and statistically significant mean value reduction and of relative percentage differences between estimated marginal means (Δ), calculated at each visits, of NRS was observed, with a maximum value (−48.5%) between the first and last visit. At the end of the treatment period 14.3% of ulcers were completely healed, 46.4% downgraded, 53.6% were stable. Overall, no ulcers upgraded. A statistically significant reduction of the Δ, between the first and last visit, for fibrinogen (−16%) was also observed.Conclusion: Rheopheresis reduced overall painful symptoms; data suggest that it could heal or improve ulcers and hemorheological laboratory parameters in HD patients with PAD and ischemic ulcers resistant to standard therapies.

1 February 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
Elisabetta SignorielloElisabetta Signoriello
Elisabetta Signoriello
DAD’Amico Alessandra
D’Amico Alessandra
MFM Fratta
M Fratta
Lorenzo UggaLorenzo Ugga
Lorenzo Ugga
CAC. Altobelli
C. Altobelli
GLG. Lus
G. Lus
Posterior fossa syndrome (PFS) is a rare manifestation of ponto-mesencephalic lesions frequently reported in post-surgical pediatric tumors, rarely described as a consequence of vascular, infective or inflammatory lesions. The aim of this article is to report the clinical and neuroradiological characteristics of a patient with an acute PFS presentation as a relapse in relapsing-remitting MS, significantly responsive to Alemtuzumab treatment. 24-year-old patient affected by multiple sclerosis developed motor-cognitive and behavioral syndrome related to an extensive ponto-mesencephalic lesion under Fingolimod treatment. Our case highlights the significant and rapid effect of Alemtuzumab therapy on both cognitive and motor symptoms occurring during a MS relapse with atypical neuroradiological localization.